Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

255
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
255
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

281
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
281
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

162
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
162
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

200
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
200
Cholinergic Antagonists: Pharmacokinetics01:24

Cholinergic Antagonists: Pharmacokinetics

437
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations,  while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...
437
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

162
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
162

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Estimating treatment effects on health utility scores for patients living with migraine: a post hoc analysis of the DELIVER trial.

Expert review of pharmacoeconomics & outcomes research·2023
Same author

Migraine: from pathophysiology to treatment.

Journal of neurology·2023
Same author

Evaluating migraine with typical aura with neuroimaging.

Frontiers in human neuroscience·2023
Same author

Non-invasive neuromodulation of the cervical vagus nerve in rare primary headaches.

Frontiers in pain research (Lausanne, Switzerland)·2023
Same author

Effectiveness and safety profile of greater occipital nerve blockade in cluster headache: a systematic review.

Journal of neurology, neurosurgery, and psychiatry·2023
Same author

Patient-reported experiences with migraine-related cognitive symptoms: Results of the MiCOAS qualitative study.

Headache·2023
Same journal

Key Considerations in Telestroke Program Management.

Continuum (Minneapolis, Minn.)·2026
Same journal

Neurology's Action Potential: Delivering on the Promise of Brain Health.

Continuum (Minneapolis, Minn.)·2026
Same journal

Erratum.

Continuum (Minneapolis, Minn.)·2026
Same journal

Management of Large Artery Atherosclerosis.

Continuum (Minneapolis, Minn.)·2026
Same journal

Thrombolysis, Thrombectomy, and Antithrombotic Therapy for Acute Ischemic Stroke.

Continuum (Minneapolis, Minn.)·2026
Same journal

Stroke in Children and Younger Adults.

Continuum (Minneapolis, Minn.)·2026
See all related articles

Related Experiment Video

Updated: Jun 29, 2025

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
10:39

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

18.2K

Indomethacin-Responsive Headache Disorders.

Peter J Goadsby

    Continuum (Minneapolis, Minn.)
    |April 3, 2024
    PubMed
    Summary
    This summary is machine-generated.

    Paroxysmal hemicrania and hemicrania continua are indomethacin-responsive headaches. Noninvasive vagus nerve stimulation offers an alternative treatment, potentially reducing indomethacin use for these chronic conditions.

    More Related Videos

    Investigating Migraine-Like Behavior Using Light Aversion in Mice
    05:23

    Investigating Migraine-Like Behavior Using Light Aversion in Mice

    Published on: August 11, 2021

    3.8K
    Author Spotlight: Deciphering Electrical Networks Behind Complex Brain Activities and Disorders
    05:49

    Author Spotlight: Deciphering Electrical Networks Behind Complex Brain Activities and Disorders

    Published on: November 1, 2024

    776

    Related Experiment Videos

    Last Updated: Jun 29, 2025

    3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
    10:39

    3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

    Published on: June 2, 2014

    18.2K
    Investigating Migraine-Like Behavior Using Light Aversion in Mice
    05:23

    Investigating Migraine-Like Behavior Using Light Aversion in Mice

    Published on: August 11, 2021

    3.8K
    Author Spotlight: Deciphering Electrical Networks Behind Complex Brain Activities and Disorders
    05:49

    Author Spotlight: Deciphering Electrical Networks Behind Complex Brain Activities and Disorders

    Published on: November 1, 2024

    776

    Area of Science:

    • Neurology
    • Headache Medicine

    Background:

    • Paroxysmal hemicrania and hemicrania continua are rare headache disorders.
    • Both conditions are characterized by severe head pain and cranial autonomic features.
    • They are part of the trigeminal-autonomic cephalalgias.

    Purpose of the Study:

    • To describe the clinical features of paroxysmal hemicrania and hemicrania continua.
    • To outline current and emerging treatment strategies for these disorders.
    • To emphasize the importance of accurate diagnosis and management.

    Main Methods:

    • Review of clinical features and treatment outcomes.
    • Discussion of pathophysiological mechanisms.
    • Emphasis on diagnostic criteria and differential diagnoses.

    Main Results:

    • Indomethacin is the primary treatment for both paroxysmal hemicrania and hemicrania continua.
    • Noninvasive vagus nerve stimulation is a promising alternative or adjunctive therapy.
    • Brain MRI, including pituitary views, is recommended for diagnosis.

    Conclusions:

    • Paroxysmal hemicrania and hemicrania continua are treatable headache disorders with appropriate recognition.
    • Indomethacin provides significant relief, but alternative treatments like vagus nerve stimulation are emerging.
    • Lifelong management and vigilance for differential diagnoses are crucial.